Avenge Bio

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

Avenge Bio Receives FDA Orphan Drug Designation for AVB-001 for the Treatment of Mesothelioma

Avenge Bio, Inc. Company Profile: Financials, Valuation, and Growth

Michael Heffernan on LinkedIn: Avenge Bio Presents Preclinical Data at the American Society of Gene &…

Rogue Trooper: Avenge the Quartz Zone Massacre (Games Workshop, 1987)

Michael Heffernan on LinkedIn: I am excited to announce the closing of Avenge Bio's $45 million Series A…

Avenge Bio

Branding Process, Monderer Design

avengebio (@AvengeBio) / X

Avenge Bio on LinkedIn: Startup Avenge Bio nabs $45M for novel cell therapy approach to ovarian…

Healthcare Weekly Pulse Check Issue #1 Jan.1-Jan.7, 2022

Avenger Bio Insecticide

Avenge Bio Closes $45 Million Series A Financing

Stanley Tam email address & phone number Avenge Bio Corporate Controller contact information - RocketReach

DelveInsight Business Research LLP on LinkedIn: Pharma News Updates for AbbVie, Novartis, Avenge Bio, Eli Lilly